Research Advances in TNF-α/TNFR1 Signaling Pathway in Inner Ear Diseases Based on TR-FRET Technology

The inner ear contains a blood-labyrinth barrier that strictly separates the bloodstream from the cochlear microenvironment and was once considered an immune-privileged organ. However, under physiological conditions, immune cells are present in areas such as the spiral ganglion, limbus, and stria vascularis of the cochlea. Among these, cochlear macrophages exhibit diverse morphologies and gene expression patterns, playing a critical role in cochlear function. Under pathological conditions, the cochlea can also recruit circulating immune cells. These immune cells, together with cochlear cells with immune functions, form a complex inflammatory response system. In response to stimuli such as infection, acoustic trauma, and ototoxic drugs, they secrete inflammatory factors through pathways like Toll-like receptors and pyroptosis, contributing to the pathogenesis of various inner ear diseases. Among these, TNF-α, IL-1, and IL-6 are the most closely associated inflammatory factors with cochlear and central auditory pathologies.

TNF-α is a peptide pro-inflammatory factor composed of 157 amino acids with a molecular weight of 17 kDa. Its biological effects are achieved by inducing leukocytes to migrate to sites of infection or injury and through binding to two receptors. TNFR1 contains a death domain in its cytoplasmic region, primarily inducing apoptosis, while TNFR2 lacks a death domain and mediates cell activation and anti-apoptotic signals via TRAF. Upon binding to TNFR, TNF-α primarily activates three signaling pathways: the NF-κB pathway, which inhibits apoptosis and promotes inflammation; the Caspase apoptosis pathway, which promotes cell death; and the MAPK/JNK pathway, which enhances the activity of various transcription factors. The TNF-α/TNFR1 assay kit based on TR-FRET technology enables efficient detection of TNF-α binding to TNFR1, providing a valuable tool for studying the role of this signaling pathway in inner ear diseases.

The primary pathological change in sensorineural hearing loss is damage to inner ear hair cells. TNF-α induces apoptosis in auditory hair cells by activating JNK, Bax, and Caspase cascades, playing a significant role in sensorineural hearing loss caused by noise-induced damage, cisplatin ototoxicity, and bacterial meningitis. After noise exposure, TNF-α upregulates p38 MAPK and JNK signaling, promoting the transcription of pro-death genes and the expression of Bax-mediated mitochondrial apoptotic proteins, leading to hair cell death. Cisplatin significantly increases TNF-α expression in the serum and cochlea, where TNF-α recruits inflammatory factors and upregulates apoptotic factors via pathways like NF-κB, inducing hair cell death. The TR-FRET TNF-α/TNFR1 assay kit can be used to quantitatively measure TNF-α binding to receptors in inner ear tissues and assess the activation state of the signaling pathway.

Neuroinflammation may be a novel mechanism underlying tinnitus. TNF-α can increase Ca2+ influx by activating NMDAR, altering neuronal responses to neurotransmitters and affecting neural plasticity. In animal models of sodium salicylate-induced tinnitus, TNF-α gene expression increases in the cochlea, inferior colliculus, cochlear nucleus, and auditory cortex, with tinnitus scores positively correlating with TNF-α and Nr2b gene expression levels. TNF-α binding to TNFR1 can influence AMPA receptor expression on cell membranes, leading to synaptic changes that mediate tinnitus development. TR-FRET technology can be used to detect the binding kinetics of TNF-α to TNFR1, providing a high-throughput analytical method for screening molecules targeting this pathway.

Etanercept, a TNF-α inhibitor, can block the expression and secretion of inflammatory cytokines in the spiral ligament, limbus, and stria vascularis, mitigating the toxic effects of TNF-α on the cochlea and auditory nerves. In noise-exposure models, etanercept improves cochlear microcirculation, ensures adequate oxygen supply in the stria vascularis, and prevents noise-induced hearing loss by protecting the endocochlear potential. In cisplatin ototoxicity models, intraperitoneal injection of etanercept inhibits the elevation of TNF-α in the serum and cochlea, reducing hair cell damage. The TR-FRET TNF-α/TNFR1 assay kit can evaluate the blocking effects of inhibitors on TNF-α-receptor binding, providing a quantitative method for drug screening and dose optimization.

IL-1 and TNF-α exhibit mutual synergy, activating downstream pathways like NF-κB and MAPK in target cells to induce cell death and inflammatory factor expression. IL-1 gene polymorphisms are significantly associated with sudden sensorineural hearing loss and Ménière's disease. IL-6 expression is primarily induced by IL-1β and TNF-α and is upregulated in cisplatin ototoxicity and noise-induced damage models. IL-6 receptor antibodies can inhibit immune cell recruitment, reduce spiral neuron loss, and decrease inflammatory cell infiltration by suppressing IL-6 signaling in the cochlea after noise exposure. TNF-α, IL-1, and IL-6 form an inflammatory network that plays a synergistic role in inner ear diseases.

Inhibiting the expression of inflammatory factors like TNF-α, IL-1β, and IL-6 and modulating their associated signaling pathways will be key strategies for treating inner ear diseases in the future. The TR-FRET TNF-α/TNFR1 assay kit provides a sensitive and efficient tool for studying the role of TNF-α signaling in inner ear diseases, applicable to mechanistic research and intervention evaluation. However, inflammation is a normal adaptive response, and indiscriminate inhibition may have adverse consequences. Further research should elucidate the regulatory network of inflammatory factors in inner ear diseases, particularly the interactions between the TNF-α/TNFR1 pathway and other pathways, to provide a theoretical basis for mechanistic studies and intervention strategies.

The "UniOne® TR-FRET Human TNF-α TNFR1 Binding Kit" (Cat. No.: UA086007), independently developed by Nanjing UA-Bio Technology Co., Ltd., is a high-performance analytical platform designed for studying the interaction between tumor necrosis factor-α (TNF-α) and its key receptor TNFR1. Based on time-resolved fluorescence resonance energy transfer (TR-FRET) technology, this kit enables precise and efficient assessment of the binding activity between human TNF-α and TNFR1, providing a stable and reliable standardized solution for research in inflammatory disease mechanisms, autoimmune drug screening, and antibody development.